Structure of PD1 and its mechanism in the treatment of autoimmune diseases

Cell Biochem Funct. 2023 Oct;41(7):726-737. doi: 10.1002/cbf.3827. Epub 2023 Jul 20.

Abstract

PD-1 and CTLA-4 can play an important role in addressing the issue of autoimmune diseases. PD-1 is a transmembrane glycoprotein expressed on T, B, and Dentric cells. This molecule functions as a checkpoint in T cell proliferation. Ligation of PD-1 with its ligands inhibits the production of IL-2, IL-7, IL-10, and IL-12 as well as other cytokines by macrophages, natural killer (NK) cells, and T cells, which can suppress cell proliferation and inflammation. Today, scientists attempt to protect against autoimmune diseases by PD-1 inhibitory signals. In this review, we discuss the structure, expression, and signaling pathway of PD-1. In addition, we discuss the importance of PD-1 in regulating several autoimmune diseases, reflecting how manipulating this molecule can be an effective method in the immunotherapy of some autoimmune diseases.

Keywords: T cells; anti-PD-1 therapy; autoimmunity; programmed cell death-1; rheumatoid arthritis; systemic lupus erythematosus; type 1 diabetes.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases* / therapy
  • Cytokines / metabolism
  • Humans
  • Inflammation
  • Programmed Cell Death 1 Receptor* / metabolism

Substances

  • Cytokines
  • Programmed Cell Death 1 Receptor
  • PDCD1 protein, human